What Is CJC-1295? The Half-Life Engineering Behind This GHRH Analog

CJC-1295 exists because of an enzyme. Not because of a discovery about growth hormone itself, or a new understanding of the pituitary, but because researchers studying growth hormone releasing hormone (GHRH) kept running into the same problem: the molecule worked, but it was gone from the bloodstream before it could do much. Understanding CJC-1295 means understanding the problem it was designed to solve, which turns out to be a more interesting story than the compound alone.

The Problem: DPP-4 and the 10-Minute Window

Growth hormone releasing hormone, the naturally occurring hypothalamic peptide that signals the pituitary to release growth hormone, has a biological half-life of roughly 10 to 20 minutes in the bloodstream. The enzyme responsible for this rapid destruction is dipeptidyl peptidase-4, commonly abbreviated DPP-4.

DPP-4 is a protease, an enzyme that cleaves peptide bonds. It targets peptides that have certain amino acids at specific positions, and GHRH is one of its substrates. When GHRH enters systemic circulation, DPP-4 begins degrading it immediately. The hypothalamus compensates by releasing GHRH in pulses, each pulse producing a burst of pituitary GH release before DPP-4 eliminates the signal. This pulsatile architecture is how the body normally manages GH secretion.

For researchers trying to study sustained GH stimulation, or clinicians wanting to maintain elevated GH signaling over hours or days rather than minutes, this half-life is a practical obstacle. The earliest GHRH analog, sermorelin (the first 29 amino acids of GHRH), has the same DPP-4 vulnerability as native GHRH. It works, but it disappears quickly, requiring frequent administration to maintain effect.

CJC-1295 was engineered to survive DPP-4.

The Engineering Solution: DPP-4 Resistance

CJC-1295 is a modified version of the first 29 amino acids of GHRH, the same region as sermorelin, with chemical substitutions at specific positions that render the peptide resistant to DPP-4 cleavage. The modifications preserve the peptide's binding affinity for the GHRH receptor on pituitary somatotrophs while removing the structural features that DPP-4 recognizes as cleavage sites.

The result is a molecule that activates the same receptor as GHRH, produces the same downstream effect (pituitary GH release), but remains intact in the bloodstream far longer. Early versions of this approach extended the half-life to hours rather than minutes, a meaningful improvement.

The version that became known as CJC-1295 includes an additional innovation: a technology called the Drug Affinity Complex, or DAC.

DAC: Binding to Albumin

Albumin is the most abundant protein in human blood plasma. Among its functions is serving as a carrier for various molecules, binding to them and extending their circulation time by shielding them from filtration and degradation. Drugs that bind to albumin are removed from circulation more slowly than unbound drugs because albumin itself has a half-life of approximately 19 days.

The DAC technology in CJC-1295 incorporates a reactive chemical group that forms a covalent bond with albumin in the bloodstream after administration. Once bound, CJC-1295 effectively adopts albumin's extended circulation time. The result is a biological half-life measured in days rather than minutes: published research documented half-lives of 6 to 8 days in human subjects, with GH pulse amplitude elevated for a week or more following a single administration.

This is a qualitatively different pharmacological profile from sermorelin or native GHRH. A single injection produces sustained GH stimulation over a period that the pulsatile administration of older compounds could not replicate.

CJC-1295 Without DAC

A distinction worth clarifying: in research and clinical contexts, "CJC-1295" is sometimes used to refer to two different compounds. CJC-1295 with DAC is the albumin-binding version described above, with the extended half-life. CJC-1295 without DAC (sometimes called Modified GRF 1-29 or Mod GRF) is the DPP-4-resistant GHRH analog without the albumin-binding chemistry. Its half-life is substantially shorter, measured in hours rather than days.

The two versions have different research profiles and different practical implications. CJC-1295 with DAC provides sustained GH elevation but does not closely replicate the pulsatile pattern of natural GH secretion. CJC-1295 without DAC, administered at appropriate intervals, more closely approximates the natural pulsatile rhythm while still providing substantially better durability than native GHRH or sermorelin.

Researchers studying GH secretagogues have examined both profiles. Whether sustained GH elevation or pulsatile GH stimulation is preferable for specific research outcomes is a question that has not been definitively resolved in the clinical literature.

What the Research Has Studied

GH pulse amplitude and IGF-1. Published clinical trials of CJC-1295 demonstrated dose-dependent increases in GH pulse amplitude and sustained elevation of IGF-1, the primary downstream mediator of GH action. A clinical study published in the Journal of Clinical Endocrinology and Metabolism showed that CJC-1295 administration produced mean GH increases of 2 to 10 fold over baseline, with IGF-1 levels elevated for more than 2 weeks following the final dose.

Body composition. The downstream effects of sustained GH and IGF-1 elevation on body composition have been examined in aging and clinical populations. GH promotes fat mobilization and lean mass preservation. Research on CJC-1295 has examined whether its extended GH stimulation profile translates to favorable changes in fat mass and lean mass ratios, with mixed results depending on the study population and duration.

Sleep architecture. Growth hormone secretion is tightly linked to slow-wave sleep. The largest natural GH pulse of the day occurs in the first deep sleep cycle. Research on GHRH analogs including CJC-1295 has examined associations with sleep quality, specifically slow-wave sleep duration. This connection reflects the bidirectional relationship between GH secretion and sleep physiology.

The Ipamorelin Pairing

CJC-1295 is frequently studied in combination with ipamorelin, and the rationale for this pairing has a clear mechanistic basis. CJC-1295 acts through the GHRH receptor. Ipamorelin acts through the ghrelin receptor (GHS-R1a). These are separate receptor systems that converge on the same target: stimulating pituitary somatotrophs to release GH.

Research has shown that simultaneous activation of both receptor systems produces a greater GH pulse amplitude than either compound alone. The two pathways are additive, and potentially synergistic at the pituitary level, because they activate GH release through distinct intracellular signaling cascades. This dual-pathway approach has been the subject of both clinical and preclinical research, and represents the primary combination studied in the growth hormone secretagogue field.

The detailed article on ipamorelin covers the ghrelin receptor pathway and ipamorelin's selectivity profile. Read alongside this article, the two pieces describe complementary halves of the most-studied secretagogue combination in current research.

Regulatory Status

CJC-1295 does not have FDA approval as a drug. It has been available through compounding pharmacies under physician prescription, though its compounding status has been subject to regulatory review. The FDA's periodic classification of research peptides affects availability, and current status should be confirmed with a licensed physician before any clinical consideration.

The research base for CJC-1295 includes published human clinical trials, which distinguishes it from many peptides that have only animal model data. The clinical trials established pharmacokinetic and GH-stimulating effects in human subjects, though they were not designed or powered to establish clinical outcomes for specific indications.